Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Terns Pharmaceuticals, a clinical-stage oncology company based in Foster City, California, has announced its participation in several upcoming investor conferences scheduled for March 2026. The senior management team will engage in fireside chats and one-on-one meetings, providing opportunities for investors to learn more about the company’s innovative pipeline and strategic direction.

The first conference is TD Cowen’s 46th Annual Health Care Conference, where Terns' management will present on March 2 at 3:50 p.m. ET in Boston. Following this, they will participate in the Leerink Global Healthcare Conference on March 9 at 1:40 p.m. ET, also in Miami. On March 10, Terns will engage in 1x1 meetings at the Barclays 28th Annual Global Healthcare Conference, before concluding their schedule at the Citizens Life Sciences Conference on March 11 at 9:00 a.m. ET, also in Miami.

Live webcasts of the fireside chats will be accessible through the investor relations section of Terns Pharmaceuticals' website, with replays available for at least 30 days post-presentation.

Terns Pharmaceuticals is dedicated to transforming traditional oncology treatments through advanced therapies. Their lead asset, TERN-701, is an allosteric BCR-ABL inhibitor that aims to improve upon existing treatments for chronic myeloid leukemia (CML) in terms of efficacy, safety, and patient convenience.

Investors interested in understanding Terns' innovative approach and future prospects are encouraged to tune into these live presentations and explore additional resources available on the company's website. For further inquiries, Terns has provided contact details for both investor and media relations.

As Terns Pharmaceuticals, Inc. (Nasdaq: TERN) prepares to participate in several notable investor conferences throughout March 2026, investors should consider the potential market impacts of these events. The company, focused on oncology therapeutics, especially its lead product TERN-701, a highly selective BCR-ABL inhibitor, may present various opportunities and risks for investors looking to position themselves strategically.

Participation in conferences like TD Cowen's 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference provides Terns with a platform to showcase its innovative treatments and update the market on clinical developments. These presentations may enhance investor confidence, particularly if the management effectively communicates the competitive advantages of TERN-701 compared to existing therapies.

Investors should closely monitor the content of these presentations and any new data that might be released. They can be pivotal in determining the stock's short-term movements. Furthermore, the increasing enthusiasm around oncology therapeutics, combined with Terns' unique positioning, could lead to significant investor interest if the company can stimulate positive sentiment.

On the operational front, Terns’ recent advancements should be supported by robust clinical trial data. Stakeholders must remain vigilant about the progress of TERN-701 and any milestones announced during these conferences, as they could reinforce bullish positions in the stock. Additionally, the live webcasts of the fireside chats will provide immediate access to Terns' updates, enabling real-time assessment of the company's messaging and reception by analysts.

As always, investors should balance enthusiasm with caution—while the oncology sector promises substantial growth, challenges and competitive pressures remain. Keeping abreast of developments in Terns Pharmaceuticals and broader industry trends will be essential for making informed investment decisions.